文献速递乳腺癌

FAIRLANE:新辅助伊帕西替尼联合紫杉醇治疗早期三阴性乳腺癌的双盲安慰剂对照随机II期试验

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
PubMed 文献 · Ann Oncol · 2019-01-01

FAIRLANE是一项随机双盲安慰剂对照II期试验,评估新辅助伊帕西替尼联合紫杉醇治疗早期三阴性乳腺癌。主要终点为意向治疗人群和PTEN低表达人群的病理完全缓解率,伊帕西替尼组与安慰剂组分别为17%对13%和16%对13%,差异无统计学显著性;伊帕西替尼组3级及以上不良事件更多(32%对16%)。

要点

  • 伊帕西替尼联合紫杉醇未显著提高早期三阴性乳腺癌的病理完全缓解率。
  • 在PIK3CA/AKT1/PTEN改变亚组中,伊帕西替尼的抗肿瘤效应最明显。
  • 伊帕西替尼组3级及以上不良事件发生率为32%,安慰剂组为16%。

核心结论

  • 在12周紫杉醇方案中加入伊帕西替尼未在临床或统计学上显著提高早期三阴性乳腺癌的病理完全缓解率,尽管MRI评估的总体缓解率在数值上更高。
  • 伊帕西替尼的抗肿瘤效应在生物标志物选择的患者中最明显。
  • 安全性与此前伊帕西替尼联合紫杉醇的经验一致。

研究设计与样本

  • 随机双盲安慰剂对照II期试验,入组早期三阴性乳腺癌患者(T≥1.5 cm,N0-2)。
  • 患者按1:1随机接受每周紫杉醇80 mg/m2联合伊帕西替尼400 mg或安慰剂(第1-21天,每28天一个周期),术前治疗12周。
  • 共同主要终点为意向治疗人群和免疫组化PTEN低表达人群的病理完全缓解率(ypT0/TisN0)。

主要发现

  • 意向治疗人群(N=151)中,伊帕西替尼组与安慰剂组的病理完全缓解率分别为17%和13%。
  • 免疫组化PTEN低表达人群(N=35)中,伊帕西替尼组与安慰剂组的病理完全缓解率分别为16%和13%。
  • PIK3CA/AKT1/PTEN改变亚组(N=62)中,伊帕西替尼组与安慰剂组的病理完全缓解率分别为18%和12%。
  • MRI评估的总体缓解率和完全缓解率在三个人群中均有利于伊帕西替尼,PIK3CA/AKT1/PTEN改变亚组的完全缓解率分别为39%和9%。
  • 伊帕西替尼组3级及以上不良事件发生率为32%,安慰剂组为16%;腹泻发生率分别为17%和1%。

关键数值与推荐

  • 病理完全缓解率(意向治疗人群,N=151):伊帕西替尼组17% vs 安慰剂组13%。
  • 病理完全缓解率(免疫组化PTEN低表达人群,N=35):伊帕西替尼组16% vs 安慰剂组13%。
  • 病理完全缓解率(PIK3CA/AKT1/PTEN改变亚组,N=62):伊帕西替尼组18% vs 安慰剂组12%。
  • MRI完全缓解率(PIK3CA/AKT1/PTEN改变亚组):伊帕西替尼组39% vs 安慰剂组9%。
  • 3级及以上不良事件发生率:伊帕西替尼组32% vs 安慰剂组16%;腹泻:伊帕西替尼组17% vs 安慰剂组1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This hypothesis-generating trial evaluated neoadjuvant ipatasertib-paclitaxel for early triple-negative breast cancer (TNBC). PATIENTS AND METHODS: In this randomized phase II trial, patients with early TNBC (T ≥ 1.5 cm, N0-2) were randomized 1 : 1 to receive weekly paclitaxel 80 mg/m2 with ipatasertib 400 mg or placebo (days 1-21 every 28 days) for 12 weeks before surgery. Co-primary end points were pathologic complete response (pCR) rate (ypT0/TisN0) in the intention-to-treat (ITT) and immunohistochemistry phosphatase and tensin homolog (PTEN)-low populations. Secondary end points included pCR rate in patients with PIK3CA/AKT1/PTEN-altered tumors and pre-surgery response rates by magnetic resonance imaging (MRI). RESULTS: pCR rates with ipatasertib versus placebo were 17% versus 13%, respectively, in the ITT population (N = 151), 16% versus 13% in the immunohistochemistry PTEN-low population (N = 35), and 18% versus 12% in the PIK3CA/AKT1/PTEN-altered subgroup (N = 62). Rates of overall and complete response (CR) by MRI favored ipatasertib in all three populations (CR rate 39% versus 9% in the PIK3CA/AKT1/PTEN-altered subgroup). Ipatasertib was associated with more grade ≥3 adverse events (32% versus 16% with placebo), especially diarrhea (17% versus 1%). Higher cycle 1 day 8 (C1D8) immune score was significantly associated with better response only in placebo-treated patients. All ipatasertib-treated patients with low immune scores and a CR had PIK3CA/AKT1/PTEN-altered tumors. CONCLUSIONS: Adding ipatasertib to 12 weeks of paclitaxel for early TNBC did not clinically or statistically significantly increase pCR rate, although overall response rate by MRI was numerically higher with ipatasertib. The antitumor effect of ipatasertib was most pronounced in biomarker-selected patients. Safety was consistent with prior experience of ipatasertib-paclitaxel. A T-cell-rich environment at C1D8 had a stronger association with improved outcomes in paclitaxel-treated patients than seen for baseline tumor-infiltrating lymphocytes. This dependency may be overcome with the addition of AKT inhibition, especially in patients with PIK3CA/AKT1/PTEN-altered tumors. CLINICALTRIALS.GOV: NCT02301988.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Oliveira M, Saura C, Nuciforo P, et al. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019. PMID: 31147675. doi:10.1093/annonc/mdz177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。